Stang et al. reported that patients who met the four criteria (effective chemotherapy before RFA, tumor diameter ≤ 3 cm, tumor number ≤ 3, and carcinoembryonic antigen ≤ 100 ng/ml) showed significantly better 5-year survival and recurrence-free survival rates of 39 and 22%, respectively, than those patients who did not meet the criteria [28]. The gene discussed is CEACAM5; the disease is neoplasm.